DARZALEX® Redefining Approaches in Early-Line Multiple Myeloma Treatment

NDMM TRANSPLANT-INELIGIBLE PATIENTS

DARZALEX® + VMP

(bortezomib + melphalan +
prednisone)

ALCYONE TRIAL

NDMM = newly diagnosed multiple myeloma.

AFTER 1 PRIOR THERAPY

DARZALEX® + Rd

(lenalidomide +
dexamethasone)

POLLUX TRIAL

DARZALEX® + Vd

(bortezomib +
dexamethasone)

CASTOR TRIAL

AFTER 2 PRIOR THERAPIES*

DARZALEX® + Pd

(pomalidomide +
dexamethasone)

EQUULEUS TRIAL

*Prior therapies included lenalidomide and a proteasome inhibitor (PI).

AFTER 3 PRIOR THERAPIES

DARZALEX®
Monotherapy

SIRIUS TRIAL

Prior therapies included a PI and an immunomodulatory agent or patients were double-refractory to a PI and an immunomodulatory agent.

Extensive clinical experience in multiple myeloma1

>52,000 Patients Treated
Estimated Worldwide Since Approval2

1166 Patients Treated With DARZALEX® in Clinical Trials1

6 Registrational Trials in Multiple Myeloma1§

 

As of June 2018. Estimate based on projected patients, calculations of demand, and duration of treatment.

§Includes 3 large, phase 3 clinical trials.

DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma:

  • in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
  • in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
  • in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
  • in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
  • as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent

Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.